期刊文献+

高效液相色谱法测定二甲苯磺酸拉帕替尼片有关物质 被引量:1

Determination of Related Substances in Lapatinib Ditosylate Tablets by HPLC
原文传递
导出
摘要 目的建立测定二甲苯磺酸拉帕替尼片有关物质的高效液相色谱法。方法采用Waters Xterra MS C18色谱柱(4.6mm×250 mm,5μm);以0.01 mol.L-1磷酸二氢钠溶液(用磷酸调节pH值至3.2)为流动相A,以乙腈为流动相B,梯度洗脱,流速1.0 mL.min-1;检测波长265 nm,柱温40℃。结果拉帕替尼杂质A、拉帕替尼杂质2和拉帕替尼杂质1分别在0.02~8.08、0.02~8.26和0.02~8.29 mg.mL-1内线性关系良好,r≥0.999 9,定量限分别为1.0、1.4、2.1 ng,杂质高、中、低浓度的平均回收率(n=9)在100.2%~102.9%,RSD(n=9)在0.02%~0.66%,可以满足杂质分析的要求。结论本方法简便、准确、专属性强,可定量测定二甲苯磺酸拉帕替尼片的有关物质。 OBJECTIVE To establish a determination method of the related substances of lapatinib ditosylate tablets by HPLC. METHODS Waters Xterra MS C18 column (4. 6 mm × 250 mm, 5 μm) was selected; 0. 01 mol . L^-1 sodium dihydrogen phosphate solution (pH adjusted to 3.2 with phosphoric acid) was mobile phase A, aeetonitrile was mobile phase B, and gradient elutiun was used at a flow rate of 1.0 mL . min^-1. The detection wavelength was set at 265 nm, and the column temperature was 40 ℃. RESULTS Lapatinib Impurity A, LAPA-2 and LAPA-1 had good linearity in the range of 0.02 - 8.08, 0.02 - 8.26 and 0.02 - 8.29 mg . m^L-1 , respectively ( r ≥ 0. 999 9). The limits of quantitation (LOQ) were 1.0, 1.4, and 2. 1 ng, respectively. The average recovery (n=9) was in the range of 100.2% - 102.9%, and RSDs (n=9) were in the range of 0.02% - 0.66%. CONCLUSION The method is simple, accurate, and specific and can quantitatively determine the related substances of lapatinib ditosylate tablets.
出处 《中国药学杂志》 CAS CSCD 北大核心 2013年第8期644-648,共5页 Chinese Pharmaceutical Journal
关键词 高效液相色谱法 二甲苯磺酸拉帕替尼片 拉帕替尼杂质A HPLC lapatinib ditosylate tablet related substance lapatinib impurity A
  • 相关文献

参考文献1

二级参考文献24

  • 1Zhou Y, Li S, Hu YP, et al. Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis. Cancer Res, 2006, 66(1) :404-411.
  • 2Xia W, Liu LH, Ho P, et al. Truncated ErbB2 receptor(p95ErbB2)is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Oncogene, 2004, 23(3):646-653.
  • 3Burris HA 3rd. Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. The Oncologist, 2004, 9 Suppl 3 : 10-15.
  • 4Versola M, Burris HA 3rd, Jones S, et al. Clinical activity of GW572016 in EGF10003 in patients with solid tumors. J Clin Oncol, 2004, 22( 14 Suppl) :3047
  • 5Stemmler J, Kahlert S, Siekiera W, et al. Brain metastases(BM) in patients treated with trastuzumab for HER2 overexpressing metastatic breast cancer(MBC) : incidence and survival. J Clin Oncol, 2005, 23( 16 Suppl) :1568.
  • 6Burris HA 3rd, Hurwitz HI, Dees EC, et al. Phase Ⅰ safety, pharmacokinetics, and clinical activity study of lapatinib(GW572016) , a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol, 2005, 23(23) :5305-5313.
  • 7Perez EA, Byrne JA, Hammond IW, et al. Results of an analysis of cardiac function in 2,812 patients treated with lapatinib. J Clin Oncol, 2006, 24(18 Suppl):583.
  • 8Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med, 2005, 353(16) :1673-1684.
  • 9Bence AK, Anderson EB, Halepota MA, et al. Phase Ⅰ pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects. Invest New Drugs, 2005, 23 ( 1 ) :39-49.
  • 10Sawaki M, Ito Y, Akiyama F, et al. High prevalence of HER-2/neu and p53 overexpression in inflammatory breast cancer. Breast Cancer, 2006, 13(2) :172-178.

共引文献4

同被引文献15

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部